Search results
Results from the WOW.Com Content Network
The mifepristone-misoprostol combination is, by far, the most recommended drug regimen for medical abortions, but other drug combinations are available. Misoprostol alone, without mifepristone, may be used in some circumstances for medical abortion, and has even been demonstrated to be successful in the second trimester. [37]
Hoeschst AG transferred all rights for medical uses of mifepristone (outside of the United States) to Exelgyn. [2] In 1999, Exelgyn won approval of Mifegyne in 11 additional countries. [3] As of 2024, Exelgyn distributes mifepristone to 40 countries, [4] but within the United States it is distributed by Danco Laboratories and GenBioPro.
In 2000, GenBioPro's generic version of mifepristone was approved for medication abortion, as part of a two-drug regimen in combination with misoprostol. In 2023, GenBioPro sued the FDA to obtain a legal judgement confirming that mifepristone could continue to be sold, in spite of anti-abortion laws passed in some states.
Mifepristone is one of two drugs used in medication abortion in the U.S. But mifepristone has many uses in reproductive care and in other contexts, experts say.
Mifepristone was developed in 1980 and came into use in France in 1987. [16] It became available in the United States in 2000, for medication abortion, and in 2010, for Cushing's syndrome. [17] [10] [12] It is on the World Health Organization's List of Essential Medicines. [18] Mifepristone was approved in Canada in January 2017. [19] [20]
Novak, who lives in Georgia, didn’t want to have a surgical abortion, so she opted for a medication abortion instead, which typically involves taking two prescription drugs, mifepristone and ...
Aid Access is a nonprofit organization that provides access to medication abortion by mail to the United States and worldwide. It describes its work as a harm reduction strategy designed to provide safe access to mifepristone and misoprostol for those able to become pregnant in the United States who may not otherwise have access to abortion or miscarriage management services. [2]
The 15 drugs accounted for $41 billion, or 14%, of total Medicare Part D spending between Nov. 1, 2023, and Oct. 1, 2024.